药物涂层球囊 alone 与联合旋磨术治疗股腘动脉支架内再狭窄的长期结局比较
该回顾性多中心观察性研究基于前瞻性注册数据,纳入2017年1月至2022年3月间治疗的106例股腘动脉支架内再狭窄患者(每组53例),中位随访3年。结果显示,与单用药物涂层球囊相比,旋磨术联合药物涂层球囊在5年无临床驱动靶病变血运重建率和无血栓生存率方面更优,且不增加主要不良肢体事件。
要点
- 旋磨术联合药物涂层球囊组5年无临床驱动靶病变血运重建率为64.0±9.4%,单用药物涂层球囊组为30.5±10.6%(P=.036)。
- 旋磨术联合药物涂层球囊组5年无血栓生存率为74.6±7.6%,单用药物涂层球囊组为37.2±10.5%(P=.026)。
- 两组间主要不良肢体事件无统计学显著差异。
核心结论
- 在股腘动脉支架内再狭窄患者中,旋磨术联合药物涂层球囊较单用药物涂层球囊减少再干预、改善辅助一期通畅率并降低血栓发生率,且不增加主要不良肢体事件。
研究设计与样本
- 回顾性多中心观察性研究,基于前瞻性注册数据,纳入2017年1月至2022年3月期间治疗的股腘动脉支架内再狭窄患者,共106例(每组53例),中位随访3年。
主要发现
- 2年无临床驱动靶病变血运重建率:旋磨术联合药物涂层球囊组为87.1±3.9%,单用药物涂层球囊组为75.5±8.7%。
- 5年无临床驱动靶病变血运重建率:旋磨术联合药物涂层球囊组为64.0±9.4%,单用药物涂层球囊组为30.5±10.6%(P=.036)。
- 5年无血栓生存率:旋磨术联合药物涂层球囊组为74.6±7.6%,单用药物涂层球囊组为37.2±10.5%(P=.026)。
- 两组间主要不良肢体事件无统计学显著差异。
- 多变量分析显示,旋磨术联合药物涂层球囊降低靶病变血运重建风险并改善辅助一期通畅率,而Tosaka 3级病变和病变长度预测更差的结局。
临床怎么用
- 对于复杂支架内再狭窄,尤其是闭塞性或长病变,旋磨术联合药物涂层球囊可能提供更有效且持久的治疗选择。
- 在缺乏明确指南推荐的情况下,旋磨术联合药物涂层球囊提供了一种基于病变特点的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate and compare the efficacy and safety of drug-coated balloon angioplasty (DEB) versus rotational atherectomy combined with DEB (RA + DEB) in patients with in-stent restenosis (ISR) in the femoropopliteal territory. METHODS: Retrospective multicenter observational study based on data from a prospective registry of patients with femoropopliteal stents treated between January 2017 and March 2022. RESULTS: One hundred and six patients were included (53 in each group) with 3 years median follow-up. At 2 years, freedom from clinically driven target lesion revascularization (CD-TLR) was 87.1 ± 3.9% in the RA + DEB group compared to 75.5 ± 8.7% in the DEB group. At 5 years, the CD-TLR rates were 64.0 ± 9.4% in RA + DEB and 30.5 ± 10.6% in DEB (P = .036). Additionally, 5-year thrombosis-free survival was significantly higher in RA + DEB (74.6 ± 7.6%) compared to DEB (37.2 ± 10.5%, P = .026). There were no statistically significant differences in MALE between the treatment groups. In multivariable analysis, RA + DEB reduced TLR risk and improved assisted primary patency, while Tosaka 3 and lesion length predicted worse outcomes. CONCLUSIONS: RA combined with DEB offers advantages over DEB alone in femoropopliteal ISR, reducing reinterventions, enhancing assisted primary patency, and lowering thrombosis rates without increasing MALE.Clinical ImpactThis study addresses the current lack of long-term evidence on the treatment of femoropopliteal in-stent restenosis (ISR) using drug-coated balloons (DEB) alone versus DEB combined with rotational atherectomy (RA). Clinically, RA+DEB significantly reduces reinterventions and thrombosis, and improves assisted primary patency without increasing complications. For clinicians, this supports a more effective and durable option for complex ISR, particularly in occlusive or long lesions. The innovation lies in demonstrating the added value of vessel preparation with RA, offering a lesion-specific strategy in the absence of clear guideline recommendations.
引用
- Molina Nácher V, Roselló Paredes JC, Núñez LG, et al. Comparative Long-Term Outcomes of Drug-Coated Balloons Alone Versus Combined Treatment with Rotational Atherectomy in the Treatment of Femoropopliteal Artery In-Stent Restenosis. J Endovasc Ther. 2025. PMID: 40169389. doi:10.1177/15266028251329757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。